Other News To Note

Metabolic Solutions Development Co., of Kalamazoo, Mich., said it received a $1.1 million multiyear Small Business Technology Transfer Program grant from the National Institute on Alcohol Abuse and Alcoholism to further evaluate MSDC-0602, an insulin sensitizer selective to mTOT, in animal models of fatty liver disease.